Cargando…

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity

Immune checkpoint inhibitors (ICIs) targeting programmed death‐1 (PD‐1), its ligand (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) have revolutionized cancer treatment by recovering the attack of T lymphocytes on the malignant cells. They have improved clinical outcomes dramaticall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xiaoxiao, Wang, Hanping, Zhou, Jiaxin, Li, Yue, Duan, Lian, Si, Xiaoyan, Zhang, Li, Fang, Ligang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Clinical Guideline
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996973/ https://www.ncbi.nlm.nih.gov/pubmed/31849171 http://dx.doi.org/10.1111/1759-7714.13250

Ejemplares similares

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
por: Lu, Minya, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
por: Duan, Lian, et al.
Publicado: (2020)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
por: Liu, Xiaowei, et al.
Publicado: (2020)

Use of glucocorticoids in the management of immunotherapy‐related adverse effects
por: Wang, Hanping, et al.
Publicado: (2020)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
por: Wang, Wenxian, et al.
Publicado: (2022)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
por: Li, Yue, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
por: Si, Xiaoyan, et al.
Publicado: (2020)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system
por: Shi, Jiayu, et al.
Publicado: (2019)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors—Associated Cardiotoxicity
por: Li, Chenghui, et al.
Publicado: (2022)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Clinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study
por: Wang, Hanping, et al.
Publicado: (2020)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
por: Cheema, Parneet K., et al.
Publicado: (2022)

Cardiotoxicity from immune checkpoint inhibitors
por: Michel, Lars, et al.
Publicado: (2019)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Cardiotoxicity risk factors with immune checkpoint inhibitors
por: Brumberger, Zachary L., et al.
Publicado: (2022)

Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)
por: Totzeck, Matthias, et al.
Publicado: (2022)

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors
por: Li, Jian, et al.
Publicado: (2018)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
por: Zhou, Yu-Wen, et al.
Publicado: (2019)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
por: Guidon, Amanda C, et al.
Publicado: (2021)

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy
por: Higham, C E, et al.
Publicado: (2018)

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity
por: Liang, Lin, et al.
Publicado: (2023)

Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases
por: Liu, Liping, et al.
Publicado: (2020)

“Neurological manifestations of COVID-19” - guideline of the German society of neurology
por: Berlit, Peter, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
por: Mascolo, Annamaria, et al.
Publicado: (2021)

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
por: Husebye, Eystein S, et al.
Publicado: (2022)

Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience
por: Xiao, Junjuan, et al.
Publicado: (2023)

Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
por: Ma, Christopher, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
por: Kluger, Harriet, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gervqb693u7d8nljas82881k1g